Physician profile
Ronald A Bloom
NPI 1659353779
$2,323.69
in general payments reported to CMS, 2019-2025
22 companies · $630 in 2025
The $630 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $525 · 2021: $14.09 · 2022: $81.40 · 2023: $447 · 2024: $232 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $525.00 | 2020 | |
| Janssen Biotech, INC. | $324.70 | 2019-2025 | Tremfya |
| Abbvie INC. | $274.77 | 2023-2025 | Skyrizi, Rinvoq |
| Ipsen Biopharmaceuticals, INC | $218.25 | 2024-2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $189.28 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $147.02 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.17 | 2019 | |
| Pfizer INC. | $98.95 | 2019-2025 | |
| Qol Medical, LLC | $66.34 | 2019-2023 | Sucraid |
| Lilly USA, LLC | $58.75 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $57.66 | 2023-2025 | Ocaliva |
| Ardelyx, INC. | $56.64 | 2025 | Ibsrela |
| Genzyme Corporation | $52.02 | 2023 | |
| Fresenius Kabi USA, LLC | $30.38 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $23.93 | 2025 | Dupixent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $23.50 | 2025 | Voquezna |
| Celgene Corporation | $20.52 | 2023 | Zeposia |
| Astellas Pharma US INC | $14.86 | 2019 | |
| Merck Sharp & Dohme LLC | $14.50 | 2019 | |
| W. L. Gore & Associates, INC. | $14.09 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.36 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$42,566.16 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.